Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 11, 2019 18:00 ET | Source: Biothera Pharmaceuticals, Inc.

Biothera Pharmaceuticals Presents Updated Phase 2 Data for Chemo-refractory Triple Negative Breast Cancer Patients at San Antonio Breast Cancer Symposium

EAGAN, Minn., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today that updated response and clinical benefit data from its ongoing Phase 2 study in chemo-refractory...
December 04, 2019 09:00 ET | Source: Biothera Pharmaceuticals, Inc.

Biothera Pharmaceuticals Phase 2 Triple Negative Breast Cancer Data Selected for Spotlight Session at San Antonio Breast Cancer Symposium

EAGAN, Minn., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that response and clinical benefit data from its Phase 2 study of dectin-1 agonist Imprime PGG in...
November 08, 2019 07:00 ET | Source: Biothera Pharmaceuticals, Inc.

Biothera Pharmaceuticals to Present Immune Pharmacodynamic Data (IPD) Showing Immune Activation in Phase 2 Melanoma and Triple Negative Breast Cancer Study

Two Late-Breaking Poster Presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Imprime PGG-induced IPD Changes Associated with Stable Disease, Progression-Free Survival and...
November 05, 2019 10:00 ET | Source: Biothera Pharmaceuticals, Inc.

Biothera Pharmaceuticals to Present Immune Pharmacodynamic and Survival Data from Phase 2 Melanoma and Triple Negative Breast Cancer Study

EAGAN, Minn., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. will present two late-breaking posters highlighting immune pharmacodynamic data from its Phase 2 clinical study in...
June 01, 2019 09:00 ET | Source: Biothera Pharmaceuticals, Inc.

Biothera Pharmaceuticals Presents Clinical Data from Phase 2 Study Evaluating the Combination of Imprime PGG and Merck’s KEYTRUDA in Triple Negative Breast Cancer at 2019 ASCO Annual Meeting

Imprime PGG is a dectin receptor agonist that triggers anti-cancer immune responsesIMPRIME 1 study enrolled 44 previously treated, metastatic triple negative breast cancer (TNBC) patients15.9% Overall...
May 16, 2019 10:00 ET | Source: Biothera Pharmaceuticals, Inc.

Biothera Pharmaceuticals to Present Clinical Data from Phase 2 Triple Negative Breast Cancer Study at ASCO 2019 Annual Meeting

EAGAN, Minn., May 16, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc., which is developing a dectin receptor agonist drug known as Imprime PGG, announced today that it will present primary...
September 05, 2018 09:15 ET | Source: Biothera Pharmaceuticals, Inc.

Biothera Pharmaceuticals Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

EAGAN, Minn., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today a clinical collaboration with AstraZeneca to evaluate whether the combination of Biothera’s Imprime...
May 16, 2018 16:10 ET | Source: Biothera Pharmaceuticals, Inc.

Biothera Pharmaceuticals Appoints Andrew D.C. LaFrence Chief Financial Officer

EAGAN, Minn., May 16, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc., announced the appointment of Andrew D.C. LaFrence, CPA as Senior Vice President and Chief Financial Officer, effective...
April 16, 2018 09:00 ET | Source: Biothera Pharmaceuticals, Inc.

Biothera Pharmaceuticals Presents Translational Data from Ongoing Clinical Trials Showing Imprime PGG in Combination with Merck’s KEYTRUDA® (pembrolizumab) Drives Innate and Adaptive Immune Responses in Tumors

EAGAN, Minn., April 16, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced the presentation of new translational data from ongoing phase 2 clinical trials combining Biothera’s...
March 26, 2018 10:00 ET | Source: Biothera Pharmaceuticals, Inc.

Preclinical Data Showing Synergy of Biothera Pharmaceuticals’ Imprime PGG and a CD40 Agonist in a Pancreatic Cancer Model Presented at Keystone Symposia

EAGAN, Minn., March 26, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. and the Abramson Cancer Center of the University of Pennsylvania announced today the presentation of new preclinical...

Next Page keyboard_arrow_right